Search

Your search keyword '"E, Mery"' showing total 130 results

Search Constraints

Start Over You searched for: Author "E, Mery" Remove constraint Author: "E, Mery"
130 results on '"E, Mery"'

Search Results

51. Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.

52. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.

53. Placenta pathology in recipient versus donor oocyte derivation for in vitro fertilization in a setting of hypertensive disorders of pregnancy and IUGR.

54. Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

55. Sentinel lymph node processing in gynecological cancer histopathology and molecular biology.

56. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.

57. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.

58. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.

59. Cannabinoid-Induced Brugada Syndrome: A Case Report.

60. Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors.

61. Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease.

62. Frozen section examination of sentinel lymph nodes can be used as a decisional tool in the surgical management of early cervical cancer.

63. Severe gynaecological involvement in Proteus Syndrome.

64. GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement.

65. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.

66. [Nomograms in routine clinical practice: Methodology, interest and limitations].

67. Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in pets.

68. Networking for ovarian rare tumors: a significant breakthrough improving disease management.

69. Lack of mutation of DICER1 and FOXL2 genes in microcystic stromal tumor of the ovary.

71. Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.

72. [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].

73. Vaginal reconstruction with pedicled vertical deep inferior epigastric perforator flap (diep) after pelvic exenteration. A consecutive case series.

74. Adherence to guidelines in gynecologic cancer surgery.

75. Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression.

76. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].

77. [The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists].

78. Prognostic relevance of celiac lymph node involvement in ovarian cancer.

79. Accuracy of intraoperative pathological examination of SLN in cervical cancer.

80. Does space make waste? The influence of ICU bed capacity on admission decisions.

81. [The management of the metastatic disease by the surgeons].

82. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study.

83. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.

84. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages.

85. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis.

86. Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset.

87. Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis.

88. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer.

89. Peritoneal pseudomyxoma arising from the urachus.

90. Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study.

91. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

92. Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.

93. Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage?

94. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis.

95. Hybrid imaging by SPECT/CT for sentinel lymph node detection in patients with cancer of the uterine cervix.

96. Incidence of micrometastases in histologically negative para-aortic lymph nodes in advanced cervical cancer patients.

97. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis.

98. [Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases].

99. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

100. Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 cases.

Catalog

Books, media, physical & digital resources